Rivaroxaban for the prevention of venous thromboembolism after radiofrequency ablation of saphenous veins concomitant with miniphlebectomy,sclerotherapy,or no treatment of varicose tributaries
Restricted accessResearch articleFirst published online October, 2021
Rivaroxaban for the prevention of venous thromboembolism after radiofrequency ablation of saphenous veins concomitant with miniphlebectomy,sclerotherapy,or no treatment of varicose tributaries
To assess the efficacy and safety of once-daily 10 mg rivaroxaban for venous thromboembolism prophylaxis after ClosureFast radiofrequency ablation (RFA) of saphenous veins.
Method
The medical records of patients, who had a Caprini score of ≥3, underwent RFA, received prophylactic rivaroxaban for five days, and completed follow up at one month were reviewed for efficacy (a combination of endovenous heat-induced thrombosis [EHIT] grade of 2–4, any symptomatic or asymptomatic deep vein thrombosis [DVT], and symptomatic pulmonary embolism [PE]) and safety (a combination of major and clinically relevant non-major [CRNM] bleeding) outcomes.
Results
The results of RFA for 248 great saphenous and 24 small saphenous veins with the concomitant miniphlebectomy (63.8%) and sclerotherapy (16.5%) were analyzed. The primary efficacy outcome occurred in 5 of 218 (2.3%; 95%CI, 1.0–5.3%) patients: three EHITs and two symptomatic DVTs. The CRNM bleeding was reported in two patients (0.9%; 95% CI, 0.2–3.3%). No difference was observed in comparison with 79 similar patients who received 40 mg of subcutaneous enoxaparin during the same time period.
Conclusion
Once-daily 10 mg rivaroxaban is suitable for VTE prophylaxis after RFA of saphenous veins.
BozkurtKALawaetzMDanielssonG, et al.
European college of phlebology guideline for truncal ablation. Phlebology2020;
35: 73–83.
2.
PavlovicMDSchuller-PetrovicSPichotO, et al.
Guidelines of the first international consensus conference on endovenous thermal ablation for varicose vein disease – ETAV consensus meeting 2012. Phlebology2015;
30: 257–273.
3.
HealyDAKimuraSPowerD, et al.
A systematic review and meta-analysis of thrombotic events following endovenous thermal ablation of the great saphenous vein. Eur J Vasc Endovasc Surg2018;
56: 410–424.
4.
KabnickLSSadekMBjarnasonH, et al.
Classification and treatment of endothermal heat-induced thrombosis: recommendations from the American venous forum and the society for vascular surgery. J Vasc Surg Venous Lymphat Disord2021;
9: 6–22.
5.
GouldMKGarciaDAWrenSM, et al.
Prevention of VTE in nonorthopedic surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest2012;
141: e227S–e277S.
6.
BahlVHuHMHenkePK, et al.
A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg2010;
251: 344–350.
7.
NietoJAEspadaNGMerinoRG, et al.
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thromb Res2012;
130: 183–191.
8.
SamamaCMLaporteSRosencherN, et al.
Rivaroxaban or enoxaparin in nonmajor orthopedic surgery. N Engl J Med2020;
382: 1916–1925.
9.
UthoffHHoltzDBrozP, et al.
Rivaroxaban for thrombosis prophylaxis in endovenous laser ablation with and without phlebectomy. J Vasc Surg Venous Lymphat Disord2017;
5: 515–523. 2017/06/19. DOI: 10.1016/j.jvsv.2016.12.002.
10.
KeoHHBaumannFDiehmN, et al.
Rivaroxaban versus fondaparinux for thromboprophylaxis after endovenous laser ablation. J Vasc Surg Venous Lymphat Disord2017;
5: 817–823.
11.
KeoHHSpinediLStaubD, et al.
Duration of pharmacological thromboprophylaxis after outpatient endovenous laser ablation: a propensity score-matched analysis. Swiss Med Wkly2019;
149: w20166–24.
12.
LobastovKBorsukDFokinA, et al.
Caprini score in venous surgery: first results from an ongoing registry study. J Vasc Surg: Venous Lymphat Disord2021;
9: 550–551.
13.
EklofBRutherfordRBBerganJJ, et al.
Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg2004;
40: 1248–1252.
14.
LabropoulosNTiongsonJPryorL, et al.
Definition of venous reflux in lower-extremity veins. J Vasc Surg2003;
38: 793–798.
15.
ProebstleTMAlmBJGockeritzO, et al.
Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. Br J Surg2015;
102: 212–218.
De MaeseneerMPichotOCavezziA, et al. Union Internationale de Phlebologie.Duplex ultrasound investigation of the veins of the lower limbs after treatment for varicose veins – UIP consensus document. Eur J Vasc Endovasc Surg2011;
42: 89–102.
18.
SchulmanSAngerasUBergqvistD, et al. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost2010;
8: 202–204.
19.
KaatzSAhmadDSpyropoulosAC, et al. Subcommittee on Control of Anticoagulation.Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost2015;
13: 2119–2126.
ErikssonBIBorrisLCFriedmanRJ, et al.
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med2008;
358: 2765–2775.
22.
KakkarAKBrennerBDahlOE, et al.
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet2008;
372: 31–39.
23.
LassenMRAgenoWBorrisLC, et al.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med2008;
358: 2776–2786.
24.
TurpieAGLassenMRDavidsonBL, et al. RECORD4 Investigators.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet2009;
373: 1673–1680.
25.
BrarRNordonIMHinchliffeRJ, et al.
Surgical management of varicose veins: meta-analysis. Vascular2010;
18: 205–220.
26.
BarkerTEvisonFBensonR, et al.
Risk of venous thromboembolism following surgical treatment of superficial venous incompetence. VASA2017;
46: 484–489.
27.
PannucciCJSwistunLMacDonaldJK, et al.
Individualized venous thromboembolism risk stratification using the 2005 caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: a meta-analysis. Ann Surg2017;
265: 1094–1103.
28.
HanhBMCuongLQSonNT, et al.
Determination of risk factors for venous thromboembolism by an adapted caprini scoring system in surgical patients. JPM2019;
9: 36–07.
29.
JohJHKimWSJungIM, et al. Consensus Working Group.Consensus for the treatment of varicose vein with radiofrequency ablation. Vasc Specialist Int2014;
30: 105–112.
30.
ShaidakovEVGrigoryanAGKorzhevskiiDE, et al.
Morphologic changes in the vein after different numbers of radiofrequency ablation cycles. J Vasc Surg Venous Lymphat Disord2015;
3: 358–363.
